Tikcro Technologies announces Q3 2008 financial results and management change
Fri. November 28, 2008; Posted: 08:40 AM
Nov 28, 2008 (M2 EQUITYBITES via COMTEX) --
TIKRF |
Quote |
Chart |
News |
PowerRating -- Tikcro Technologies Ltd. (OTC BB: TIKRF), a company that has holdings
in BioCancell Therapeutics Inc, a clinical-stage biopharmaceutical
company, announced yesterday (27 November) its financial results for
the third quarter and nine months ended 30 September 2008.
A
The company's net income for the third quarter that ended 30 September
2008 was USD550,000 (USD0.07 per share), up when compared to USD61,000
(USD0.01 per diluted share) for the same quarter of 2007.
A
The net income for the nine months which ended 30 September 2008 was
USD479,000 (USD0.06 per diluted share) an improvement over the net
income of USD162,000 (USD0.02 per diluted share) in the third quarter a
year ago.
A
The company had cash and marketable securities totalling USD7.8m as of
30 September 2008. In July 2008, Tikcro acquired common stock, a
convertible note and a warrant of BioCancell for a total amount of
USD2.5m.
A
Tikcro further stated that Eric Paneth has been appointed as a member
of the board of directors, as its CEO. He has agreed to serve in the
position of CEO for no consideration. Aviv Boim, Tikcro's former chief
executive officer, will continue to serve as Tikcro's nominee to the
board of directors of BioCancell, as noted in the company's prior US
Securities and Exchange Commission filings.
Comments on this story may be sent to admin@m2.com
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index